According to 10Q, 3 new SAB members: In Septem
Post# of 148152
In September 2022, the Company appointed to its Scientific Advisory Board (“SAB”): Dr. Jordan Lake to assist with trial design for HIV/NASH and identifying collaborative opportunities, Dr. Stefan Glück to assist with identifying partners, trial design, identifying collaborations, and opportunities in oncology, and Dr. Naoto Ueno to assist with trial design and identifying opportunities for collaboration in oncology.